THE EUROPEAN MEDICINES Agency (EMA) has recommended authorising Moderna’s Covid-19 vaccine for children ages 12 to 17, the first time the shot has been authorised for people under 18.

The EU drug regulator said research in more than 3,700 children aged 12-17 showed that the Moderna vaccine, which is already approved for adults across Europe, produced a comparable antibody response.

Until now, the vaccine made by Pfizer and German partner BioNTech has been the only option for children as young as 12 in North America and Europe.

The US Food and Drug Administration is currently considering whether to extend the use of the Moderna vaccine to the same age group.

With global vaccine supplies still tight, much of the world is struggling to immunise adults.

EMA has just approved the #COVID19vaccine Spikevax, previously known as COVID-19 Vaccine Moderna, for children aged 12 to 17 in the 🇪🇺.
👉https://t.co/pnxvNYXDBH pic.twitter.com/WZgUz7G19K

— EU Medicines Agency (@EMA_News) July 23, 2021

The World Health Organisation and other agencies have urged wealthy countries to donate their doses to the developing world, where fewer than 2% of people have been vaccinated, rather than moving on to inoculate their less vulnerable populations.

Hundreds of millions of Moderna doses have already been administered to adults, and the company says the two-dose vaccine is just as protective for adolescents.

In a study of more than 3,700 children aged 12-17, the vaccine triggered the same signs of immune protection.

No positive Covid-19 cases arose in the vaccinated group compared with four cases among those given dummy shots.

Sore arms, headache and fatigue were the most common side effects in the young vaccine recipients, the same ones as for adults.

However, US and European regulators have cautioned that both the Moderna and Pfizer vaccines appear linked to an extremely rare reaction of chest pain and heart inflamation in teens and young adults.

Both Pfizer and Moderna have begun testing in even younger children, from 11 down to six months old. These studies are more complex: teens receive the same dose as adults, but researchers are testing smaller doses in younger children.

The EU drug regulator said it would continue to monitor the safety and efficacy of the Moderna vaccine in children as it is used in European member countries.